Liqun leads in vitro and in vivo pharmacology for the Wyss Brain Targeting Program (BTP). The BTP, co-led by Don Ingber and Jim Gorman, aims to address unmet needs in delivery of drugs and diagnostics to the central nervous system. Liqun’s research focuses on identifying and validating novel next-generation antibody shuttle compounds that efficiently facilitate the transport of drugs and diagnostics across the BBB and into the brain. In this role, she leads the ongoing development and implementation of a state-of-the-art antibody shuttle discovery platform comprising an organ-on-a-chip blood-brain barrier (BBB) model, multiple related cellular assays, and humanized transgenic mouse models.
Prior to joining the Wyss, Liqun had extensive experience in academic research and product development in industry. During her academic career at Brigham and Women’s Hospital, Harvard Medical School, Liqun profoundly contributed to mechanistic investigation and therapeutic discovery for several neurodegenerative diseases, including Alexander disease, Alzheimer’s disease and Parkinson’s disease. At BioLegend, Inc. Liqun was actively involved in antibody and immunoassay development and validation for the neuroscience portfolio. Collaborating with the Michael J. Fox foundation, Liqun initiated the development of a highly specific and sensitive immunoassay to quantify oligomeric alpha-synuclein species in biological fluids.
Liqun obtained her Ph.D. degree in Molecular and Cellular Biology from University of Kentucky and her B.S. degree from Fudan University in China.